TORONTO (Reuters) – Canadian pharmaceutical billionaire couple Barry and Honey Sherman were murdered in a targeted killing, Toronto police investigators said on Friday in their first detailed comments on the case since the couple’s bodies were found on Dec. 15.
Police said they are treating the case as a double murder, but declined to say if they had any suspects.
The Shermans were found hanging by belts from a railing next to a swimming pool at their Toronto mansion, police said.
Toronto homicide detective Susan Gomes said at a press conference that authorities believed the Shermans were targeted, but did not elaborate.
Police have “an extensive list of people we’re looking forward to speaking to,” she said.
The Sherman family said in a statement that it had expected police would classify the deaths as homicides.
The family hired a private investigator in late December and conducted an independent autopsy after complaining that police mishandled the case in its early days.
Citing unnamed police sources, multiple news organizations had reported last month that investigators were operating on the working theory that the deaths were a murder-suicide.
Gomes said those reports were wrong and that investigators initially reviewed three possibilities: double suicide, murder suicide and double homicide.
Sherman was 75 and his wife was 70. Their deaths stunned the worlds of Canadian business, politics and philanthropy, and drew public condolences from prominent figures including Canadian Prime Minister Justin Trudeau, who attended a memorial service on Dec. 21 that was broadcast on television.
Barry Sherman founded Apotex Inc in 1974 and built it into a pharmaceutical giant before stepping down as chief executive in 2012. He and his wife were known for their donations to hospitals, universities and Jewish organizations.
Separately, Apotex said on Friday that its Chief Executive Jeremy Desai had resigned and would be replaced by his predecessor and company co-founder Jack Kay.
Apotex is in a legal dispute with Teva Pharmaceuticals Industries
An Apotex representative said Desai’s departure was not related to Teva’s lawsuit against Apotex.
Reuters could not immediately reach Desai for comment.
(Reporting by Anna Mehler Paperny, Matt Scuffham and Amran Abocar; Editing by Jim Finkle, Bernadette Baum and Daniel Wallis)